What Are GLP-1s Really Doing to Your Body?
Join Dr. James Odell for Season 2 of the Science of Self-Healing Podcast! He's the medical and executive director for BRMI, as well as a practicing naturopathic doctor for over 35 years, and he's here to share with you his extensive knowledge of medicine from a different perspective.
GLP-1 medications are everywhere right now — and so is the noise around them. One side calls them a miracle. The other says they're wrecking your metabolism, your gut, and your muscle. Neither version holds up when you actually read the evidence.
In this episode, we look at what these drugs are really doing inside the body. What happens when appetite is switched off for months at a time. Why losing weight and losing strength can happen simultaneously — and what the DXA data from the STEP 1 trial actually showed about lean mass. Why two-thirds of the weight tends to come back after stopping, and what a thoughtful exit plan looks like. Plus two interactions almost nobody warns patients about: what slowed stomach emptying does to oral birth control, and why your anesthesia team needs to know you're on one of these before any procedure.
We also give the benefits their due. The SELECT trial showed a roughly 20 percent reduction in major cardiovascular events in high-risk patients — that's not a cosmetic result, and it deserves to be part of an honest conversation.
Then we turn to the bioregulatory question that sits underneath all of it: is this intervention restoring your body's ability to regulate itself, or is the benefit only holding as long as the drug keeps pressing down? Along the way, we look at emerging research on Akkermansia muciniphila, a gut bacterium that may influence your own GLP-1 signaling from the inside.
The same medication can be rational treatment for one person and a poor biological trade for another. This episode is about knowing which one you are.
Transcript: What Are GLP-1s Really Doing to Your Body?
Hello, everyone, and welcome to the Science of Self-Healing podcast. For health and wellness knowledge from a different perspective. Produced by the Bioregulatory Medicine Institute, also known as BRMI. We are your source for unparalleled information about how you can naturally support your body's ability to regulate, adapt, regenerate, and self-heal. I'm your host, Dr. James Odell, the medical and executive director for BRMI, as well as a practicing naturopathic doctor for over 35 years. And remember, this podcast is for informational purposes only and is not intended to be a substitute for the direct care of a qualified health professional who oversees and provides unique and individual care. The information here is to broaden our different perspectives and should not be construed as medical advice or treatment. Let's get started.
Today we're talking about GLP-1 medications — the drugs you've been hearing about under names like Ozempic, Wegovy, Mounjaro, and Zepbound. Here's what I want to cover. I'll start with what GLP-1 actually is inside your body, and how these medications differ from the hormone you make on your own. Then we'll get into what they do to appetite and the brain, what the evidence really says about mood, and what happens when someone stops taking them.
After that we'll talk about digestion, including a couple of interactions almost nobody hears about — one involving birth control pills and one involving surgery and anesthesia. Then we'll look at muscle and bone, because what kind of weight you lose matters just as much as how much.
From there, the benefits, which are real and substantial for the right patient. Then the warnings that deserve attention, who needs to be especially careful, why the source of the product matters, and finally what a bioregulatory approach to all of this looks like — including some interesting new research on a gut bacterium that seems to nudge your body's own GLP-1 signaling. That's a lot of ground, so let's get moving.
The Hormone You Already Make
So, let's start with the hormone itself. GLP-1 stands for glucagon-like peptide-1. It's a hormone your body makes on its own, mostly in response to eating. It helps coordinate a whole cluster of things — your blood sugar, your insulin release, a hormone called glucagon that raises blood sugar when you need it raised, how fast your stomach empties, and how hungry or full you feel.
The medications are called GLP-1 receptor agonists. That word "agonist" just means something that flips the switch. These drugs imitate part of that natural signaling system, but they're engineered to stay active in your body far longer than the hormone you make yourself.
Semaglutide is the long-acting version sold as Ozempic and Wegovy. Tirzepatide, sold as Mounjaro and Zepbound, works a little differently because it flips two switches instead of one — GLP-1 and another gut hormone called GIP. Those are all FDA-approved products.[6,7,8] Compounded and other unapproved versions are a separate matter, and I'll come back to that later, because it turns out to matter quite a bit.
Why a Drug Is Not the Same as a Hormone
Now here's the distinction I want you to hold onto for the rest of this episode.
A hormone your body makes rises and falls. It responds to your meals, your blood sugar, your nervous system, whatever metabolic state you happen to be in. A long-acting medication doesn't do that. It creates a steady, sustained signal that can last for days.
That doesn't automatically make it harmful. But pushing on a receptor with a drug is not the same thing as restoring your body's own ability to regulate that pathway. The result can still be genuinely valuable — less hunger, smaller meals, better blood sugar, real weight loss, and in the right patients, fewer heart attacks and strokes.[5] It just isn't biologically neutral.
The Question Underneath the Scale
Which brings me to the question underneath all of this.
A bioregulatory approach asks more than whether the number on the scale went down. It asks whether the intervention actually improves your body's ability to regulate appetite, blood sugar, digestion, body composition, strength, and energy — or whether the improvement only holds as long as the drug keeps pressing on the pedal.
For a lot of people with obesity, diabetes, or cardiovascular disease, long-term medical treatment may be completely reasonable. Obesity can behave like a chronic, relapsing disease, and needing ongoing treatment isn't a personal failure. The more useful question is what's being gained, and what's being traded away to get it. And the honest answer is that it depends — on the patient, the reason for treatment, the dose, nutritional status, how fast the weight is coming off, the person's underlying health, the quality of the product, and the quality of the medical follow-up.
Food Noise, and Why Hunger Still Matters
So, let's start with the brain. GLP-1 medications reduce appetite partly through pathways in the central nervous system. A lot of people describe a dramatic drop in intrusive thoughts about eating — what's often called "food noise." For someone dealing with severe obesity, diabetes, or compulsive overeating, that can feel like an enormous relief.
But I want to be careful here, because appetite isn't just an inconvenience. Hunger is also a protective signal.
When appetite gets strongly suppressed, people can go weeks eating too little protein, too little fat, not enough fiber, not enough vitamins and minerals, and not enough total food — without ever feeling the biological urgency that would normally push them to eat. And if there's nausea on top of that, or early fullness, or things suddenly tasting wrong, intake can drop even further.
So you can end up with someone who looks like a metabolic success on paper — weight down, blood sugar down — while quietly becoming undernourished. That distinction really matters. The goal shouldn't be to erase hunger. It should be to quiet a dysregulated appetite just enough to improve the disease, while still preserving good nutrition, strength, function, and honestly, some enjoyment of food.
This gets especially important in older adults, in people who already have low muscle mass, in anyone with a history of an eating disorder, and in people at a normal or only slightly elevated weight who are using these drugs mainly to be thinner.
And when strong appetite suppression goes on for months, monitoring may need to look at more than calories. Depending on someone's diet, symptoms, age, and medical history, a clinician might want to check whether protein intake is adequate and look at things like iron, ferritin, vitamin B12, folate, vitamin D, and calcium.
Mood: Where Both Sides Got Ahead of the Evidence
Next, I'd like to talk about mood, because this is an area where I think both sides have gotten ahead of the evidence.
There have been real concerns raised about depression, emotional flatness, loss of pleasure, and suicidal thinking. Those symptoms should never be brushed aside. But we also shouldn't assume the drug caused them.
In April of 2026, the FDA reported that its review of clinical trials and observational data had not found evidence that these medications cause suicidal thoughts or actions — though it noted a very small risk couldn't be completely ruled out.[1]
So the right response is monitoring, not alarm. New depression, unusual behavior changes, significant anxiety, or suicidal thinking all deserve prompt clinical attention no matter what's ultimately determined to be causing it. And a good clinician will also ask whether the symptoms might be coming from chronic nausea, from simply not eating enough, from the body changing fast, or from a mood disorder or eating disorder that was already there.
What Happens When You Stop
So what happens when someone stops? These medications aren't addictive in the usual sense. There's no high, no intoxication, no drug-seeking behavior. But the body can become dependent on their appetite-suppressing effect to hold the new weight.
In the STEP 1 extension study, participants regained about two-thirds of the weight they'd lost within a year of stopping semaglutide. Several of the metabolic improvements drifted back toward where they started, too.[2]
Now, that doesn't mean the drug permanently damaged anyone's metabolism. Here's what's actually going on. Weight loss itself creates biological adaptation. As your body gets smaller, it needs fewer calories. And your body responds to weight loss by turning up hunger and other signals that push you back toward your previous weight. The medication was holding that pressure down. Take it away, and the pressure is still there — but now you're in a smaller body that needs less food.
That's why the exit plan matters as much as the entry plan. If someone wants to come off a GLP-1, that should be a conversation with the prescribing clinician, not just a decision to skip the next injection. A thoughtful transition means watching appetite as it returns, keeping protein up, staying with resistance exercise, protecting sleep and activity, tracking blood sugar and other markers, and mentally preparing for the fact that hunger is going to come back.
And there's one more piece. If a lot of muscle was lost on the way down, drifting back toward the old weight without deliberately rebuilding that muscle can leave someone with a worse body composition than they started with. Which is a good segue, but before I get there, I want to talk about the gut.
Your Gut on a Slower Clock
Slowing down stomach emptying is one of the ways these drugs make you feel full and blunt the blood sugar spike after a meal. That's the intended effect. But it's the same mechanism behind nausea, vomiting, reflux, bloating, constipation, and abdominal pain.
Most of those side effects are mild or temporary. But "common" doesn't mean harmless once symptoms start interfering with hydration, nutrition, sleep, or normal daily life.
The Wegovy prescribing information warns about severe gastrointestinal reactions and says the drug isn't recommended for people with severe gastroparesis — that's a condition where the stomach already empties far too slowly on its own. Reports after the drug went to market have included intestinal obstruction and severe constipation, including impaction.[3]
Persistent vomiting or diarrhea can lead to dehydration, disturbances in electrolytes like sodium and potassium, and acute kidney injury.
And severe or ongoing abdominal pain — especially pain that goes through to the back, or comes with vomiting — needs to be evaluated, not written off as a routine side effect. Pancreatitis, which is inflammation of the pancreas, and gallbladder disease are both on the list of things to consider. GLP-1 therapy and rapid weight loss in general are associated with gallbladder problems. The evidence on pancreatitis is less consistent, so it would be wrong to say it's inevitable and equally wrong to say there's nothing to watch for.
The Birth Control Interaction Almost Nobody Mentions
Now, there's a second consequence of slowed stomach emptying that I think deserves much more attention than it gets. If your stomach is emptying more slowly, pills you swallow may not be absorbed the same way.
This is especially well documented with tirzepatide. The current Zepbound prescribing information states that delayed gastric emptying can affect how oral medications are absorbed. It specifically warns that tirzepatide may reduce the effectiveness of oral birth control — particularly right after starting the drug and after every dose increase.[7]
Women using oral contraceptives are advised to switch to a non-oral method, or add a barrier method, for four weeks after starting tirzepatide and for four weeks after each dose escalation.[7]
That's a real-world consequence of changing digestive physiology that has nothing to do with feeling full.
Before Any Surgery or Sedation, Speak Up
There's another one, and this could be life-threatening, so I want to be specific.
Slowed stomach emptying can leave food in the stomach even after someone has fasted the standard amount of time before a procedure. Pulmonary aspiration — food or fluid getting into the lungs — has been reported during general anesthesia and deep sedation in patients taking these medications.[3,7]
So if you're having surgery, or a colonoscopy, or anything requiring sedation, tell the anesthesia team exactly which medication you take, your dose, when you last took it, and whether you're having any nausea, vomiting, bloating, constipation, or early fullness. And follow their instructions about when to stop, rather than deciding on your own.
Does It Really Destroy Your Microbiome?
Next, I'd like to touch on the microbiome, because there's a lot of exaggeration out there.
Changing how much you eat, when you eat, how much fiber you get, how varied your diet is, and how fast things move through your intestines can all reasonably be expected to change the intestinal environment. But claims that these drugs permanently destroy the microbiome haven't been established.
The defensible concern is indirect. If appetite suppression leaves someone eating almost no fiber, with a narrow diet, chronic constipation, poor nutrition, or repeated vomiting, then intestinal health can suffer — because the environment that feeds and supports those microbes has changed. So the target should be normal digestive function. Severe constipation, chronic vomiting, or being unable to eat is not evidence that the medication is working.
What Kind of Weight Are You Actually Losing?
Now let's talk about muscle and bone, because this is one of the most overlooked parts of the conversation.
Weight loss is never purely fat. In a body composition substudy of the STEP 1 trial, using DXA scanning — that's the same imaging used for bone density tests, which can also separate fat from lean tissue — semaglutide produced large reductions in total fat and in visceral fat, the deep fat packed around the organs. But total lean body mass also dropped by nine point seven percent over sixty-eight weeks.[4]
Let me put that in context, because it's easy to misread. Lean mass isn't only muscle. It includes water and other non-fat tissue. And because fat fell proportionally more, overall body composition actually improved. But in absolute terms, lean mass went down.
That matters, because skeletal muscle is where you dispose of glucose. It drives your mobility, your strength, your resting metabolic rate, your balance, how well you recover from illness, and how much reserve you have when something goes wrong.
So a person can weigh less and be weaker at the same time. The risk goes up when strong appetite suppression is combined with too little protein, weight coming off very fast, and little or no resistance training. It's most concerning in older adults and in anyone starting out with low muscle mass or frailty, because sarcopenia — age-related muscle loss — increases the risk of falls, disability, and losing independence.
In younger people, chronic under-fueling can interfere with training recovery, concentration, temperature regulation, menstrual cycles, and the years when bone mass is supposed to be built in the first place.
Bone, Loading, and the Long View
Weight loss also reduces the mechanical load on your bones. Combine that with not enough energy, protein, calcium, vitamin D, sex hormones, or resistance exercise, and the environment for maintaining bone gets less favorable.
Now, current evidence does not justify saying semaglutide causes osteoporosis. The more reasonable concern is a combination — fast weight loss, low nutrient intake, less loading on the bone, and whatever vulnerability the person already had.
The goal of weight-loss treatment should be preferential fat loss with muscle, strength, and metabolic reserve preserved. Not the lowest possible number on the scale.
Now the Benefits — And They Are Real
So, I've spent a lot of time on the risks. Now I want to be just as clear about the benefits, because they're substantial and it would be dishonest to skip them.
GLP-1 receptor agonists improve blood sugar regulation by increasing insulin release when glucose is elevated, and by quieting glucagon signaling that's pushing sugar up when it shouldn't be. Used on their own, the risk of blood sugar dropping too low is relatively small — that risk goes up when they're combined with insulin or with older diabetes drugs called sulfonylureas. Better glucose control means less long-term damage to blood vessels, kidneys, nerves, and eyes.
One caution there. Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy — damage to the blood vessels in the retina — in people who already have it.[3] So eye monitoring matters for those patients.
The Heart Data That Changes the Argument
And then there's the cardiovascular data, which is probably the strongest argument against treating these drugs as universally harmful.
In the SELECT trial, seventeen thousand six hundred and four adults with overweight or obesity and established cardiovascular disease, but without diabetes, were followed for about forty months. Major cardiovascular events occurred in six point five percent of participants on semaglutide compared with eight percent on placebo. That's roughly a twenty percent reduction in relative risk.[5]
That's a meaningful clinical outcome, not a cosmetic one. For someone with significant obesity and existing heart disease, those benefits may clearly outweigh the risks of treatment. For a healthy, normal-weight person using a poorly supervised product to drop a few pounds, the benefit side of that equation gets very small while the risks of undernutrition and lost metabolic reserve stay exactly where they were. Same medication. Rational treatment in one person, a bad biological trade in another.
Heart Rate, Kidneys, and Hydration
A couple of other things worth knowing. Semaglutide can modestly raise resting heart rate, and the labeling recommends watching for sustained increases.[3] And kidney injury linked to these drugs is usually secondary to dehydration rather than the drug being directly toxic to the kidney. Persistent vomiting, diarrhea, or very low fluid intake can leave someone seriously volume-depleted. Older adults, people with kidney disease, people on diuretics, and anyone who struggles to stay hydrated have less margin there.
The Thyroid Warning, Read Correctly
Next, I want to address the thyroid warning, because it comes up constantly and it's usually described inaccurately.
Both semaglutide and tirzepatide caused thyroid C-cell tumors in rodents. Whether they cause medullary thyroid carcinoma in humans is genuinely unknown. So the boxed warning reflects an unresolved question, not proof of human thyroid cancer. What it does mean is that these medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or of a genetic condition called Multiple Endocrine Neoplasia type 2.[3,7]
It would be inaccurate to say these drugs are proven to cause thyroid cancer in people. It would be just as wrong to shrug off the warning.
Pregnancy and Reproductive Planning
On pregnancy — weight-loss medications are not appropriate during pregnancy. For semaglutide, current labeling recommends stopping the medication when pregnancy is recognized, and stopping it at least two months before a planned pregnancy, because the drug stays in the body a long time.[3] Rapid weight loss and inadequate calorie intake can also interfere with menstrual cycles and reproductive function indirectly. So anyone who might become pregnant should be talking about contraception and pregnancy planning before starting treatment, not after.
Who Needs to Be Extra Careful
So who needs extra caution overall? The benefit-risk calculation deserves a much harder look in people with severe gastroparesis or other significant motility problems; a personal or family history of medullary thyroid carcinoma or MEN 2; previous pancreatitis or significant gallbladder disease; diabetic retinopathy; pregnancy or plans for pregnancy in the near term; an eating disorder or strong restrictive tendencies; low baseline muscle mass or frailty; a pattern of getting dehydrated; medications that raise the risk of low blood sugar; or a normal body weight with no real medical reason to lose more.
Age, nutritional status, muscle reserve, medical history, and the actual reason for treatment matter at least as much as which drug is on the label.
Where the Product Comes From Matters
Which brings me to where the product comes from. FDA-approved products have standardized formulations, tested dosing devices, manufacturing controls, and prescribing information that's been reviewed. Unapproved compounded versions are a different situation. The FDA has reported adverse events involving compounded semaglutide and tirzepatide, and has flagged dosing errors, dose increases happening too fast, product quality problems, and the use of certain semaglutide salt forms that aren't the same active ingredient found in approved medications.[6]
Adverse-event reports alone don't prove a product caused an event. But they underline something worth remembering: risk isn't determined by the molecule by itself.
Building Regulation, Not Just Losing Weight
So, let's talk about what a more bioregulatory strategy looks like — whether someone is on medication or starting with lifestyle first. The aim either way is to improve the body's underlying regulation rather than just move the scale.
Fiber from vegetables, fruits, legumes, oats, whole grains, and resistant starches supports fullness, blood sugar control, intestinal health, and the fermentation your gut microbes depend on. Adequate protein supports muscle, satiety, repair, and resilience. Healthy fats from olive oil, avocados, nuts, seeds, eggs, and fatty fish support nutritional adequacy and normal metabolic function. Fermented foods may support microbial diversity when they're well tolerated. Regular physical activity improves insulin sensitivity, and progressive resistance training is especially important during weight loss, because it gives your body a reason to hold onto muscle. Sleep, hydration, stress regulation, meal quality, and cutting back on highly refined foods all feed into this too.
The Gut Bacterium Worth Watching
Now, here's a piece of research I find genuinely interesting.
There's a beneficial gut bacterium called Akkermansia muciniphila, associated with the integrity of the intestinal barrier and with metabolic health. Research suggests it may influence your body's own GLP-1 signaling, through interactions between the microbiome and the hormone-producing cells lining the intestine.
A 2026 randomized controlled trial in adults with metabolic syndrome found that a pasteurized form of this bacterium increased GLP-1 responses in certain participants — with the biggest metabolic improvements in the people who started out with the lowest levels of Akkermansia. Another 2026 trial found supplementation helped limit weight regain after weight loss. Promising, though not yet definitive.
What I want you to notice is that this is a fundamentally different approach from sustained pharmacologic stimulation of the receptor. Supporting Akkermansia may help influence your own incretin signaling — incretins being the gut hormones, including GLP-1, that respond to a meal — within its normal physiological context. That said, it is not an established substitute for medication when there's a clear medical reason for treatment.
And I'd add one caution about the broader lifestyle piece. Yes, certain foods, nutrients, exercise, and microbial byproducts can influence your own GLP-1 secretion. But eating a fiber-rich meal that naturally stimulates GLP-1 is not the same thing as injecting semaglutide, and I'd encourage you to be skeptical of anyone selling you a "natural Ozempic." The real value of these lifestyle changes isn't that they boost one hormone. It's that they help restore the whole interconnected set of systems controlling insulin sensitivity, appetite, muscle, digestion, sleep, and energy balance.
The Bottom Line: Discernment, Not Fear
So let me bring this together. What are GLP-1s really doing to your body? GLP-1 receptor agonists have produced meaningful benefits in type 2 diabetes, in obesity, and in certain high-risk cardiovascular patients. They also carry real risks — gastrointestinal effects that can become severe, gallbladder disease, pancreatitis warnings, dehydration-related kidney injury, changes in how oral medications are absorbed, aspiration risk around anesthesia, modest increases in heart rate, retinopathy complications in vulnerable patients, and thyroid tumor warnings based on animal studies.[3,7] Significant weight loss can also come with loss of lean mass, especially when appetite suppression leaves protein and calories too low.[4] And weight regain after stopping is well documented.[2]
What has not been established are the sweeping claims — that these drugs permanently wreck your metabolism, inevitably cause gastroparesis, directly cause thyroid cancer in humans, erase your personality, or permanently destroy everyone's microbiome.
And here's the thing that I think gets lost. The longest rigorous evidence we have runs years — not the many decades that would actually be relevant to a young person starting one of these drugs primarily to be thinner. That uncertainty should encourage thoughtful prescribing rather than either blind enthusiasm or exaggerated fear.
Responsible treatment starts with a legitimate indication and a clearly defined goal. And monitoring has to mean more than pounds. It means nutrition, protein, hydration, bowel function, nausea, strength, activity, muscle preservation, other medications, glucose control, eye history where it applies, gallbladder and pancreatic symptoms, reproductive plans, psychological health, and whether this is something the person can realistically sustain.
If someone is steadily losing strength, can't eat a nutritionally adequate diet, is chronically dehydrated, needs repeated rescue treatment for constipation, or is vomiting persistently, continued weight loss should not be celebrated as success.
From a bioregulatory perspective, the objective is improved health with the least disruption to the systems that keep the body resilient. These medications become harmful when the biological costs exceed the disease risk they were meant to reduce. For carefully selected high-risk patients, they can deliver substantial benefit within the timeframes we've studied — though longer-term risks may still emerge over decades of use that current evidence simply can't see yet. For poorly selected patients, especially people chasing cosmetic thinness without underlying disease, the same pharmacology may trade visible weight loss for an invisible loss of nutritional and metabolic reserve.
So the most responsible message here is neither celebration nor fear. It's discernment.
Understand why the medication is being recommended. Understand what benefit you're actually trying to achieve. Know which risks apply specifically to you. And make sure your nutritional status, your muscle mass, your digestion, and your overall resilience are improving right alongside that number on the scale.
That's all for this episode. For more on this, I wrote an article on GLP-1 medications that was published in the fiftieth issue of the BRMI E-Journal on May first, 2025.
Tune in again in two weeks for another episode of The Science of Self-Healing.
Till then, be well.
Selected Sources
[1] U.S. Food and Drug Administration. "Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions with GLP-1 Receptor Agonists." April 3, 2026.
[2] Wilding, John P. H., et al. "Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide: The STEP 1 Trial Extension." Diabetes, Obesity and Metabolism 24 (2022): 1553–1564.
[3] U.S. Food and Drug Administration. Wegovy (Semaglutide) Prescribing Information.
[4] Wilding, John P. H., et al. "Impact of Semaglutide on Body Composition in Adults with Overweight or Obesity: Exploratory Analysis of STEP 1." Journal of the Endocrine Society 5, suppl. 1 (2021): A16–A17.
[5] Lincoff, A. Michael, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine 389 (2023): 2221–2232.
[6] U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Updated June 15, 2026.
[7] U.S. Food and Drug Administration. Zepbound (Tirzepatide) Prescribing Information. 2026.
[8] U.S. Food and Drug Administration. "Drug Trials Snapshots: Mounjaro." Original approval May 13, 2022; and "FDA Approves New Medication for Chronic Weight Management," November 8, 2023.
Thank you for your time today, and remember that this podcast is made possible by the Bioregulatory Medicine Institute, also known as BRMI, a nonprofit, global, non political, non commercial institute to promote the science and art of bioregulatory medicine. We extend our gratitude to each and every one of you for listening today, and if you haven't already, make sure to visit us at brmi.online. A treasure trove of invaluable information awaits you there. Connect with us across various social media platforms as well. Come and become a member of our thriving tribe. If you've enjoyed today's episode, we invite you to show your support by rating us, leaving us a review, or sharing the podcast within your circle. Our podcast and mission flourish through sharing, and your participation means the world to us. Our organization is sustained by donations, each of which is tax deductible and fuels projects like this. Visit our website, brmi.online, to contribute or simply to explore the wealth of uncensored and impartial information we offer. No contribution is too small. In just two weeks, we'll be back delving into another captivating topic. Until then, we thank you once again for listening. May wellness and wisdom be your path. Be well.
Bioregulatory medicine is a total body (and mind) approach to health and healing that aims to help facilitate and restore natural human biological processes. It is a proven, safe, gentle, highly effective, drugless, and side-effect-free medical model designed to naturally support the body to regulate, adapt, regenerate, and self-heal. BRMI is a non-commercial 501(c)(3) foundation and will expand and flourish with your support. Our goal is to make bioregulatory medicine a household term.
This article is for informational purposes only and is not intended to be a substitute for the direct care of a qualified health practitioner who oversees and provides unique and individualized care. The information provided here is to broaden our different perspectives and should not be construed as medical advice, diagnosis, or treatment.
